News | July 18, 2022
Glaucoma Research Foundation launches catalyst for a to prevent and cure neurodegeneration
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Blood contains a mixture of exosomes secreted from nearly all tissues and cells, and exosomes from other tissues can mask changes caused by disease, making it difficult to detect the presence of biomarkers that reflect disease
Empowers the lab to do more in less time within the existing floor plan by integrating clinical chemistry and immunoassay testing onto a single platform
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
It is used to control, prevent and normalize the symptoms associated with Alzheimer's disease, attention disorder, bipolar disorder, Parkinson's disease among others
he financing was significantly oversubscribed with high demand from both existing and new investors.
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Subscribe To Our Newsletter & Stay Updated
